Last reviewed 2026-04-20 · How we verify

Huluc63 (elotuzumab)

Huluc63 works by binding to the SLAMF7 protein on the surface of cancer cells, stimulating the immune system to attack and kill the cells.

Huluc63 (elotuzumab) is a SLAMF7-directed Immunostimulatory Antibody developed by Bristol Myers Squibb. It targets the SLAM family member 7 and is used to treat multiple myeloma and relapse multiple myeloma. Huluc63 is a patented product and is not yet off-patent. It was FDA approved in 2015 and is still commercially available. Key safety considerations include infusion reactions and cytopenias.

At a glance

Mechanism of action

Elotuzumab is humanized IgG1 monoclonal antibody that specifically targets the SLAMF7 (Signaling Lymphocytic Activation Molecule Family member 7) protein. SLAMF7 is expressed on myeloma cells independent of cytogenetic abnormalities. SLAMF7 is also expressed on Natural Killer cells, plasma cells, and at lower levels on specific immune cell subsets of differentiated cells within the hematopoietic lineage.Elotuzumab directly activates Natural Killer cells through both the SLAMF7 pathway and Fc receptors. Elotuzumab also targets SLAMF7 on myeloma cells and facilitates the interaction with Natural Killer cells to mediate the killing of myeloma cells through antibody-dependent cellular cytotoxicity (ADCC). In preclinical models, the combination of elotuzumab and lenalidomide resulted in enhanced activation of Natural Killer cells that was greater than the effects of either agent alone and increased anti-tumor activity in vitro and in vivo.

Approved indications

• Multiple myeloma
• Relapse multiple myeloma

Common side effects

• Fatigue
• Diarrhea
• Pyrexia
• Constipation
• Cough
• Peripheral Neuropathy
• Nasopharyngitis
• Upper Respiratory Tract Infection
• Decreased Appetite
• Pneumonia
• Hyperglycemia
• Pain in Extremities

Key clinical trials

• Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (PHASE2)
• MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) (PHASE3)
• A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (PHASE3)
• Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma (PHASE3)
• LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma (PHASE2)
• A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma (PHASE3)
• Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD) (PHASE2)
• Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Huluc63 CI brief — competitive landscape report
• Huluc63 updates RSS · CI watch RSS
• Bristol-Myers Squibb portfolio CI